LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

LLY

1,063.79

-1.23%↓

JNJ

222.81

-0.32%↓

ABBV

215.58

+1.54%↑

UNH

377.18

-0.59%↓

MRK

115.96

+0.86%↑

Home・Akcijų sąrašas・Zai Lab Ltd ADR

Zai Lab Ltd ADR

Uždarymo kaina

SektoriusSveikatos priežiūra

17.18 0.35

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

16.24

Max

17.24

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-607K -51M
Pardavimai	-28M 100M
Pelnas, tenkantis vienai akcijai	-0.46
Pelno marža	-51.215
Darbuotojai	1,784
EBITDA	4.1M -44M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+83.15% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-08-06

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-308M 2.1B
Ankstesnė atidarymo kaina	16.83
Ankstesnė uždarymo kaina	17.18

Naujienos nuotaikos

By Acuity

34%

66%

79 / 344 reitingas Healthcare

Zai Lab Ltd ADR Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-06-01 23:48; UTC

Rinkos pokalbiai

Nikkei May Rise on Optimism Over AI Demand -- Market Talk

2026-06-01 23:38; UTC

Įsigijimai, susijungimai, perėmimai

Google Seeks $80 Billion for AI Buildout; Berkshire Will Buy $10 Billion Stake -- WSJ

2026-06-01 23:37; UTC

Rinkos pokalbiai

Oil Edges Higher; Trump Seeks to Quell Israel-Hezbollah Conflict -- Market Talk

2026-06-01 23:01; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-06-01 23:01; UTC

Rinkos pokalbiai

Dexus Stuck in 'Too Hard' Basket -- Market Talk

2026-06-01 22:08; UTC

Įsigijimai, susijungimai, perėmimai

Alphabet to Issue $80 Billion of Equity for AI Buildout. Berkshire to Buy $10 Billion. -- Barrons.com

2026-06-01 22:01; UTC

Įsigijimai, susijungimai, perėmimai

Alphabet to Issue $80 Billion of Equity for AI Buildout. Berkshire to Buy $10 Billion. -- Barrons.com

2026-06-01 22:01; UTC

Įsigijimai, susijungimai, perėmimai

Google Seeks to Raise $80 Billion for AI Infrastructure -- Update

2026-06-01 21:55; UTC

Įsigijimai, susijungimai, perėmimai

Greg Abel's Week Is Off to Quite a Start -- WSJ

2026-06-01 21:53; UTC

Rinkos pokalbiai

Strong Earnings Suppress Concerns About Oil Market -- Market Talk

2026-06-01 21:22; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Berkshire's Abel Takes Big Swing With Back-to-Back Deals -- Market Talk

2026-06-01 20:50; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Tech, Media & Telecom Roundup: Market Talk

2026-06-01 20:50; UTC

Rinkos pokalbiai

Health Care Roundup: Market Talk

2026-06-01 20:50; UTC

Rinkos pokalbiai

Auto & Transport Roundup: Market Talk

2026-06-01 20:46; UTC

Įsigijimai, susijungimai, perėmimai

The Odds SpaceX Merges With Tesla Are Higher Than You Think -- Barrons.com

2026-06-01 20:22; UTC

Įsigijimai, susijungimai, perėmimai

Array Digital Infrastructure Doesn't Expect Additional Divs in 2026

2026-06-01 20:21; UTC

Įsigijimai, susijungimai, perėmimai

Array Digital Infrastructure Div Payable June 25 to Hldrs of Record June 11

2026-06-01 20:21; UTC

Įsigijimai, susijungimai, perėmimai

Array Digital Infrastructure Declares $11 Special Div

2026-06-01 20:20; UTC

Įsigijimai, susijungimai, perėmimai

Array Completes Sale of Select Spectrum Assets to Verizon for $1B

2026-06-01 19:40; UTC

Rinkos pokalbiai

Remittances to Mexico Rise for Third Straight Month -- Market Talk

2026-06-01 19:28; UTC

Rinkos pokalbiai

BoC Official Reiterates Need to Improve Business Investment -- Market Talk

2026-06-01 19:01; UTC

Rinkos pokalbiai

Oil Futures Rise On Concerns About U.S.-Iran Talks -- Market Talk

2026-06-01 18:58; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Snap 3-Session Winning Streak -- Market Talk

2026-06-01 18:54; UTC

Įsigijimai, susijungimai, perėmimai

Berkshire Stock Drops. Its Bargain-Priced Deal for Home Builder Fails to Impress Investors. -- Barrons.com

2026-06-01 18:33; UTC

Rinkos pokalbiai

Mexican PMIs Show Sluggish Manufacturing in May -- Market Talk

2026-06-01 18:32; UTC

Rinkos pokalbiai

Precious Metals Fall to Start June -- Market Talk

2026-06-01 18:00; UTC

Įsigijimai, susijungimai, perėmimai

Marsh McLennan Agency Completes Acquisition Of TriBridge Partners >MRSH

2026-06-01 17:18; UTC

Rinkos pokalbiai

Global Asset Managers Accumulate Canadian Government Debt -- Market Talk

2026-06-01 17:18; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-06-01 17:10; UTC

Rinkos pokalbiai

Įsigijimai, susijungimai, perėmimai

Salesforce Estimated to Get $225M Sales Boost From Contentful -- Market Talk

Akcijų palyginimas

Kainos pokytis

Zai Lab Ltd ADR Prognozė

Kainos tikslas

By TipRanks

83.15% į viršų

12 mėnesių prognozė

Vidutinis 32.4 USD 83.15%

Aukščiausias 44 USD

Žemiausias 21.6 USD

Remiantis 4 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Zai Lab Ltd ADR kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

4 ratings

Pirkti

Laikyti

Parduoti

Remiantis 4 analitikų, pateikusių Zai Lab Ltd ADR akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Rinkos nuotaikos

By Acuity

79 / 344 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Zai Lab Ltd ADR

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.